AstraZeneca/Targacept: Another nail in the coffin for TC-5214
This article was originally published in Scrip
Executive Summary
The latest Phase III data for AstraZeneca and Targacept's TC-5214 in major depressive disorder (MDD) are likely to spell the end for the product, say analysts at Datamonitor. Earlier this week, the two companies released top-line data from the second Phase III trial from their clinical programme, RENAISSANCE 2, showing that it did not meet its primary endpoint, change in the Montgomery-Asberg Depression Rating Scale (MADRS) total score after eight weeks of adjunct treatment with TC-5214, as compared to placebo (scripintelligence.com, 20 December 2011).